This medication is an antineoplastic agent, prescribed for lymphocytic leukemia either alone or with other medications. It stops cancer cell growth.
Contraindicated in patients with inflammation of pancreas and bleeding due to prior therapy with this medication and hypersensitivity.
The recommended dose of elspar is 6, 000 International Units/mē intramuscularly (IM) or intravenously (IV) three times a week.
It comes as a solution for injection to be administered by a healthcare provider into the vein or into the large muscle.
Caution should be exercised in patients with history of liver, kidney or pancreatic disease, any allergy, who are taking other medications, elderly, during pregnancy and breast-feeding.
It may cause dizziness or drowsiness, do not drive a car or operate machinery while taking this medication.
It may reduce platelet counts, avoid injury or bruising.
Avoid any vaccination during the treatment period.
Nausea and vomiting, loss of appetite, depression, tiredness, confusion, restlessness or agitation and headache.
Monitor complete blood counts, uric acid level and blood glucose level regularly while taking this medication.
Avoid using contaminated solution of this medication.
Avoid excess dosage.
Normally handled and stored by healthcare providers.
Cholestatic jaundice occurs when the flow of bile (chole) between the liver and small intestine is ...
Opportunistic infections are microbial infections that can cause disease in persons with a weak ...
The state health insurance programs provide health care support to the below poverty line (BPL) ...View All